OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Obesity & Metabolism is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Person‐reported outcomes in diabetes care: What are they and why are they so important?	875376689
COVID‐19 infection may cause ketosis and ketoacidosis	324
Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis	289
An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines	267
Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis	185
Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19	174
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension	142
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications	130
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update	130
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity	123
The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, retrospective, observational study in Wuhan	116
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study	113
Prediabetes and the risk of heart failure: A meta‐analysis	101
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review	101
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials	89
Influence of diabetes mellitus on the severity and fatality of SARS‐CoV‐2 (COVID‐19) infection	87
Hybrid closed‐loop therapy: Where are we in 2021?	84
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets	83
Exposure to dipeptidyl‐peptidase‐4 inhibitors and COVID‐19 among people with type 2 diabetes: A case‐control study	80
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis	78
Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome	76
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk	75
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes	73
Why is hyperglycaemia worsening COVID‐19 and its prognosis?	70
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users	70

Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study	69
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials	64
Relationship between obesity and severe COVID‐19 outcomes in patients with type 2 diabetes: Results from the CORONADO study	63
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme	62
Obesity as a risk factor for COVID‐19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease	62
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study	59
Association of obesity with postacute sequelae of COVID‐19	57
Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study	57
The PREVIEW intervention study: Results from a 3‐year randomized 2 x 2 factorial multinational trial investigating the role of protein, glycaemic index and physical activity for prevention	56
Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover st	55
Association between prediabetes and adverse outcomes in heart failure	54
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know	54
Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials	53
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials	53
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes	51
Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study	51
The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective	51
Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested posi	50
Diabetes, obesity and COVID‐19: A complex interplay	45
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study	45
Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta‐analysis	45